Free Trial

Halozyme Therapeutics (HALO) Competitors

Halozyme Therapeutics logo
$54.17 +0.42 (+0.79%)
As of 12:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HALO vs. BIIB, UTHR, INCY, EXEL, NBIX, BMRN, EXAS, RGEN, MDGL, and IONS

Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.

Halozyme Therapeutics vs.

Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.

Halozyme Therapeutics has a net margin of 43.74% compared to Biogen's net margin of 16.87%. Halozyme Therapeutics' return on equity of 157.78% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics43.74% 157.78% 25.34%
Biogen 16.87%14.98%8.76%

Biogen received 1295 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 69.06% of users gave Halozyme Therapeutics an outperform vote.

CompanyUnderperformOutperform
Halozyme TherapeuticsOutperform Votes
529
69.06%
Underperform Votes
237
30.94%
BiogenOutperform Votes
1824
71.28%
Underperform Votes
735
28.72%

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500.

Halozyme Therapeutics currently has a consensus target price of $61.90, indicating a potential upside of 15.16%. Biogen has a consensus target price of $191.30, indicating a potential upside of 51.46%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
2 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.17
Biogen
0 Sell rating(s)
20 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.38

Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$1.08B6.11$281.59M$3.7614.30
Biogen$9.82B1.89$1.63B$10.1312.47

In the previous week, Biogen had 17 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 29 mentions for Biogen and 12 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.34 beat Halozyme Therapeutics' score of 0.86 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
10 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
23 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Biogen beats Halozyme Therapeutics on 10 of the 18 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HALO vs. The Competition

MetricHalozyme TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$6.62B$2.93B$5.33B$8.39B
Dividend YieldN/A1.64%5.21%4.11%
P/E Ratio15.6731.1826.7119.71
Price / Sales6.11398.78386.47120.65
Price / Cash12.35168.6838.2534.62
Price / Book18.223.236.774.50
Net Income$281.59M-$72.35M$3.23B$248.22M
7 Day Performance3.33%2.49%0.48%-0.78%
1 Month Performance-8.01%2.45%9.10%11.53%
1 Year Performance22.38%-24.98%18.56%8.99%

Halozyme Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HALO
Halozyme Therapeutics
4.8553 of 5 stars
$54.17
+0.8%
$61.90
+14.3%
+18.2%$6.67B$1.08B15.78390
BIIB
Biogen
4.8942 of 5 stars
$129.44
+3.1%
$191.30
+47.8%
-43.9%$18.97B$9.82B11.578,720Positive News
UTHR
United Therapeutics
4.9772 of 5 stars
$305.31
0.0%
$392.00
+28.4%
+11.7%$13.77B$2.99B13.41980Positive News
Analyst Revision
INCY
Incyte
4.8728 of 5 stars
$63.81
+0.8%
$73.53
+15.2%
+10.8%$12.35B$4.41B236.342,320Positive News
EXEL
Exelixis
4.094 of 5 stars
$44.69
-1.6%
$38.94
-12.9%
+104.1%$12.19B$2.30B25.251,220Positive News
Insider Trade
NBIX
Neurocrine Biosciences
4.8714 of 5 stars
$122.82
+1.5%
$162.00
+31.9%
-14.6%$12.16B$2.41B37.331,200Positive News
BMRN
BioMarin Pharmaceutical
4.9421 of 5 stars
$59.41
+0.2%
$93.45
+57.3%
-24.1%$11.39B$2.95B27.003,080Positive News
Insider Trade
EXAS
Exact Sciences
4.6351 of 5 stars
$56.94
+0.9%
$70.90
+24.5%
+5.6%$10.74B$2.83B-10.226,400Positive News
RGEN
Repligen
4.821 of 5 stars
$126.19
-0.2%
$173.25
+37.3%
-27.1%$7.09B$650.43M-247.432,020Positive News
Gap Down
MDGL
Madrigal Pharmaceuticals
4.5252 of 5 stars
$290.72
-0.1%
$416.33
+43.2%
+16.3%$6.45B$317.38M-11.5990Positive News
IONS
Ionis Pharmaceuticals
4.4105 of 5 stars
$34.03
+1.4%
$56.67
+66.5%
-12.5%$5.42B$717.25M-11.19800Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:HALO) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners